1. The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
- Author
-
Ramona Cassin, Veronica Mattiello, Alessandro Noto, and Gianluigi Reda
- Subjects
Anemia ,Chronic lymphocytic leukemia ,Review ,hemolytic ,medicine.disease_cause ,idelalisib ,Autoimmunity ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Immune system ,immune system diseases ,ibrutinib ,hemic and lymphatic diseases ,medicine ,venetoclax ,Venetoclax ,business.industry ,autoimmune ,General Medicine ,medicine.disease ,anemia ,chemistry ,030220 oncology & carcinogenesis ,Ibrutinib ,Immunology ,Medicine ,Autoimmune hemolytic anemia ,Idelalisib ,business ,CLL ,030215 immunology - Abstract
Autoimmune cytopenias (AICs) have been reported as a common complication in chronic lymphocytic leukemia (CLL) with autoimmune hemolytic anemia (AIHA), accounting for most cases. According to iwCLL guidelines, AICs poorly responsive to corticosteroids are considered indication for CLL-directed treatment. Chemo-immunotherapy has classically been employed, with variable results, and little data are available on novel agents, the current backbone of CLL therapy. The use of idelalisib in the setting of AICs is controversial and recent recommendations suggest avoiding idelalisib in this setting. Ibrutinib, through ITK-driven Th1 polarization of cell-mediated immune response, is known to produce an immunological rebalancing in CLL, which stands as a fascinating rationale for its use to treat autoimmunity. Although treatment-emergent AIHA has rarely been reported, ibrutinib has shown rapid and durable responses when used to treat AIHA arising in CLL. There is poor evidence regarding the role of BCL-2 inhibitors in CLL-associated AICs and the use of venetoclax in such cases is debated. Furthermore, their frequent use in combination with anti-CD20 agents might represent a confounding factor in evaluating their efficacy. In conclusions, because of their ability to mitigate an immunological dysregulation that is (at least partly) responsible for autoimmunity in CLL, to date BTK-inhibitors stand out as the most suitable choice when treatment of autoimmune cytopenias is required.
- Published
- 2021